[go: up one dir, main page]

UY33236A - Inhibidores dimericos de las iap - Google Patents

Inhibidores dimericos de las iap

Info

Publication number
UY33236A
UY33236A UY0001033236A UY33236A UY33236A UY 33236 A UY33236 A UY 33236A UY 0001033236 A UY0001033236 A UY 0001033236A UY 33236 A UY33236 A UY 33236A UY 33236 A UY33236 A UY 33236A
Authority
UY
Uruguay
Prior art keywords
iap
dimeric
dimeric inhibitors
formula
inhibitors
Prior art date
Application number
UY0001033236A
Other languages
English (en)
Inventor
Christopher Sean Straub
Chen Zhuoliang
Mark G Palermo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY33236A publication Critical patent/UY33236A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

El presente invento proporciona compuestos de la fórmula M-L-M´(donde M y M´ son cada uno, de manera independiente, una fracción monomérica de la fórmula (I) y L es un enlazador). Se ha encontrado que los compuestos diméricos son efectivos para promover la apoptosis en células que se estén dividiendo rápidamente.
UY0001033236A 2010-02-25 2011-02-21 Inhibidores dimericos de las iap UY33236A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30811410P 2010-02-25 2010-02-25
US33392710P 2010-05-12 2010-05-12
US38841010P 2010-09-30 2010-09-30

Publications (1)

Publication Number Publication Date
UY33236A true UY33236A (es) 2011-09-30

Family

ID=44476672

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033236A UY33236A (es) 2010-02-25 2011-02-21 Inhibidores dimericos de las iap

Country Status (13)

Country Link
US (1) US8445440B2 (es)
EP (1) EP2539333A1 (es)
JP (1) JP2013520466A (es)
KR (1) KR20130010894A (es)
CN (1) CN102834389A (es)
AR (1) AR080253A1 (es)
BR (1) BR112012021291A2 (es)
CA (1) CA2790302A1 (es)
EA (1) EA201201177A1 (es)
MX (1) MX2012009894A (es)
TW (1) TW201141846A (es)
UY (1) UY33236A (es)
WO (1) WO2011104266A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
CA2850330A1 (en) 2011-09-30 2013-04-04 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
WO2014025759A1 (en) * 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Iap antagonists
CA2930030A1 (en) * 2012-11-09 2014-05-15 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of inhibitors of apoptosis
JP6785653B2 (ja) 2013-06-25 2020-11-18 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ 細胞内感染の処置方法
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US5281620A (en) 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
JP2002037626A (ja) 2000-07-27 2002-02-06 Internatl Superconductivity Technology Center ビスマス系高温超電導体の製造方法。
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US7229617B2 (en) 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
RU2006131553A (ru) 2004-02-05 2008-03-10 Новартис АГ (CH) Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap
US7309792B2 (en) 2004-03-01 2007-12-18 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
WO2006020060A2 (en) 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Iap binding compounds
ES2456671T3 (es) 2005-02-25 2014-04-23 Tetralogic Pharmaceuticals Corporation Inhibidores diméricos de IAP
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AU2006279929A1 (en) 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
RU2418807C2 (ru) 2005-10-25 2011-05-20 Аегера Терапьютикс Инк. Соединения, связывающие bir домены iap
EP2606933A3 (en) 2005-12-20 2014-10-15 Novartis AG Combination of an IAP-inhibitor and a taxane
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
AU2007254033A1 (en) 2006-03-21 2007-11-29 Joyant Pharmaceuticals, Inc. Small molecule apoptosis promoters
US8202902B2 (en) 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
SG171682A1 (en) 2006-05-16 2011-06-29 Aegera Therapeutics Inc Iap bir domain binding compounds
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100144650A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US8143426B2 (en) 2006-07-24 2012-03-27 Tetralogic Pharmaceuticals Corporation IAP inhibitors
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
BRPI0715195A2 (pt) 2006-07-24 2013-06-11 Tetralogic Pharm Corp composto, mÉtodos para induzir e para estimular a apoptose em uma cÉlula, para intensificar a apoptose de cÉlulas patogÊnicas in vivo em um indivÍduo, e para tratar uma doenÇa, e, composiÇço farmacÊutica
PE20080951A1 (es) * 2006-08-02 2008-09-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
EP2076778A2 (en) 2006-10-19 2009-07-08 Novartis AG Organic compounds
WO2008066854A2 (en) 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
EA200900691A1 (ru) * 2006-11-28 2009-12-30 Новартис Аг Применение ингибиторов iap для лечения острого миелоидного лейкоза
KR101149449B1 (ko) 2007-03-20 2012-05-25 삼성전자주식회사 오디오 신호의 인코딩 방법 및 장치, 그리고 오디오 신호의디코딩 방법 및 장치
AU2008240153B2 (en) 2007-04-12 2013-01-31 Joyant Pharmaceuticals, Inc. SMAC mimetic dimers and trimers useful as anti-cancer agents
PE20090211A1 (es) 2007-04-30 2009-04-02 Genentech Inc Inhibidores de las iap
EP2156189A1 (en) 2007-05-07 2010-02-24 Tetralogic Pharmaceuticals Corp. Tnf gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins
KR101584823B1 (ko) 2007-09-12 2016-01-22 제넨테크, 인크. 포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
CN101909631B (zh) 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
WO2009089502A1 (en) 2008-01-11 2009-07-16 Genentech, Inc. Inhibitors of iap
KR20100119768A (ko) 2008-01-24 2010-11-10 테트랄로직 파마슈티칼스 코포레이션 아이에이피 억제제
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
AU2009261919A1 (en) 2008-06-27 2009-12-30 Pharmascience Inc. Bridged secondary amines and use thereof as IAP BIR domain binding compounds
CA2730448A1 (en) 2008-08-02 2010-02-11 Genentech, Inc. Inhibitors of iap
US20120009141A1 (en) 2008-08-07 2012-01-12 Pharmascience Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
AU2009293403A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. IAP inhibitors
US20110287001A1 (en) 2008-09-22 2011-11-24 Tetralogic Pharmaceuticals Method of treatment
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic

Also Published As

Publication number Publication date
US8445440B2 (en) 2013-05-21
CA2790302A1 (en) 2011-09-01
EA201201177A1 (ru) 2013-04-30
MX2012009894A (es) 2012-09-12
AU2011219862A1 (en) 2012-09-06
US20110206690A1 (en) 2011-08-25
KR20130010894A (ko) 2013-01-29
JP2013520466A (ja) 2013-06-06
TW201141846A (en) 2011-12-01
BR112012021291A2 (pt) 2016-10-25
AR080253A1 (es) 2012-03-21
EP2539333A1 (en) 2013-01-02
WO2011104266A1 (en) 2011-09-01
CN102834389A (zh) 2012-12-19

Similar Documents

Publication Publication Date Title
UY33794A (es) Inhibidores diméricos de las iap
UY33236A (es) Inhibidores dimericos de las iap
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
ECSP13013074A (es) Nuevos derivados de piridina
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CO7240375A2 (es) Compuestos tricíclicos sustituidos como inhibidores del fgfr
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CR20150250A (es) Nuevos derivados de piridina
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
CR20140464A (es) Compuestos de heterociclilo
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
ECSP12012174A (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
MX2019010602A (es) Inhibidores de cdk.
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
CU20140025A7 (es) Pirimidinas anilladas sustituidas
UY34333A (es) ?métodos y composiciones para el control de malezas, y métodos para reducir la expresión de enzima dhps?
CR20150204A (es) Nuevos derivados de piridina
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
DOP2011000382A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
CR20150447A (es) Nuevos derivados de pirazol
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
CO6741154A2 (es) Compuestos de triazolopiridina
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
CL2012000508A1 (es) Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas.
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200616